Innovimmune’s INV-71 program targets ROR gamma, a master control switch of immune system activation. This novel therapeutic approach combines multiple anti-tumor mechanisms with a single agent NME promoting anti-tumor immunity through RORg agonism. It has potential as a monotherapy, and in combination, to augment current checkpoint inhibitors in development and synergize with adoptive cell therapies. RORg activation with INV-71 would be expected to provide a superior safety profile associated with the absence of generalized immunosuppression; minimal off-target and on-target toxicities.

The INV-71 program is currently being fast-tracked through lead optimization for multiple Immuno-Oncology disease indications.